Shots:

• The EC has approved Xofluza (baloxavir marboxil) for uncomplicated influenza in patients aged≥12yrs. Additionally- the EC has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged≥12yrs.
• The approval follows the CHMP’s positive opinion for Xofluza and is based on P-III CAPSTONE-1- CAPSTONE-2 and BLOCKSTONE studies
• Xofluza is a first-in-class- single-dose oral therapy- reduces the societal burden of influenza with a rapid reduction in viral replication

 ­ Ref: GlobeNewswire | Image: Roche